CN115060835B - Clopidogrel intermediate and impurity detection method - Google Patents
Clopidogrel intermediate and impurity detection method Download PDFInfo
- Publication number
- CN115060835B CN115060835B CN202210659088.2A CN202210659088A CN115060835B CN 115060835 B CN115060835 B CN 115060835B CN 202210659088 A CN202210659088 A CN 202210659088A CN 115060835 B CN115060835 B CN 115060835B
- Authority
- CN
- China
- Prior art keywords
- impurity
- impurities
- clopidogrel
- solution
- high performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The invention discloses a method for detecting clopidogrel intermediates and impurities, which adopts high performance liquid chromatography to detect and analyze the clopidogrel intermediates and the impurities, wherein a chromatographic column used in the high performance liquid chromatography is a chromatographic column with octadecylsilane bonded silica gel as a filler. According to the method for detecting clopidogrel intermediates and impurities, provided by the invention, the clopidogrel intermediates and 5 related impurities thereof are separated and detected by adopting specific reversed-phase high performance liquid chromatography analysis conditions, so that the separation and quantitative detection of the clopidogrel intermediates and 5 related substances thereof can be effectively realized, and the influence of the impurities on the quality of a final clopidogrel product is reduced.
Description
Technical Field
The invention relates to the technical field of pharmaceutical analytical chemistry, in particular to a method for detecting clopidogrel intermediates and impurities.
Background
The mechanism of cardiovascular and cerebrovascular disease is mainly due to atherosclerosis. Atherosclerosis is a complex systemic disease that occurs primarily in the aorta, coronary arteries, carotid arteries, cerebral arteries, renal arteries, extremity arteries, mesenteric arteries. Atherosclerosis is particularly detrimental to the coronary arteries supplying the heart muscle, resulting in acute coronary syndrome, a condition that results in a sudden decrease in blood flow to the heart, clinically manifested as myocardial infarction and potential cardiac arrest.
To date, antiplatelet drugs remain the cornerstone for the treatment of atherosclerotic thrombotic diseases, and clopidogrel has absolute advantage among many antiplatelet drugs. Among them, clopidogrel bisulfate has been proven to be an effective antithrombotic agent in experimental models of thrombosis, and studies have shown that clopidogrel bisulfate is more effective in preventing platelet aggregation than ticlopidine and aspirin even at low doses, and 75 mg of clopidogrel bisulfate is more effective than 325 mg of aspirin, thus gradually becoming an alternative to conventional antiplatelet therapies. Clopidogrel bisulfate is widely used as a platelet aggregation inhibitor for treating heart attacks caused by thrombus blockage or strokes caused by atherosclerosis.
Clopidogrel is a colorless oil, its bisulfate is a white solid powder, and the systematic chemical name of clopidogrel bisulfate is: (alpha S) -alpha- (2-Chlorophenyl) -6, 7-dihydrothiaeno [3,2-c]pyridine-5(4H)-aceticacidmethylester；Methyl-(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate；(+)-Methyl-α-5-[4,5,6,7-tetrahydro[3,2-c]thienopyridyl]- (2-chlorofhe-yl) acetate. Clopidogrel bisulfate has a molecular formula of C 16 H 18 ClNO 6 S 2 The structural formula is as follows:
in the chemical synthesis of clopidogrel, an intermediate of the formula:
the molecular formula of the clopidogrel intermediate is as follows: c (C) 15 H 17 Cl 2 NO 2 S, S; molecular weight 346.27; CAS number 141109-19-5; the chemical name is (S) -2- (2-chlorophenyl) -2- ((2- (thiophen-2-yl) ethyl) amino) acetic acid methyl ester hydrochloride; the above-mentioned chloropyrroleThe quality of the intermediate has a great influence on the quality and yield of the final product, i.e. clopidogrel, so that the intermediate is usually strictly controlled as a key control point.
The synthesis process of the clopidogrel intermediate comprises the following steps:
in the process of synthesizing the above-mentioned clopidogrel intermediates, various impurities are generally introduced. And medicines are used as special commodities, and related institutions such as the national food and medicine administration and the like put forward higher standards for quality safety control of medicines. In the pharmaceutical industry, there is a need to pay attention not only to the high yields of the products, but also to the chemicals and reaction by-products remaining in the products, as it relates to the quality and safety of the drugs. The development of the quality analysis method of the medicine is to analyze and detect the specific development method of the starting materials, intermediates and finished products in the synthetic process route of the medicine and verify the method. Therefore, the multi-component medicine analysis method with simple development and good reproducibility is an important means for ensuring the medicine quality.
(S) 2-o-chlorophenyl 2 ((2-thiophenoethyl) amino) acetic acid methyl ester hydrochloride is a key intermediate for preparing clopidogrel bulk drug. In the research and development process of raw medicines, research and control of impurities are a very critical link. The intermediate, especially the impurity of key intermediate has direct influence on the property and quality of intermediate itself, if the intermediate has no quality standard requirement, the quality of final product will be affected, thus having great influence on human safety.
The Chinese patent publication No. CN112851631A discloses an impurity of clopidogrel bisulfate intermediate, a preparation method thereof and a content control method thereof, but only one impurity can be detected, which still has great influence on the quality of the final clopidogrel product.
Disclosure of Invention
The invention aims to provide a method for detecting clopidogrel intermediates and impurities, which adopts specific reversed-phase high performance liquid chromatography analysis conditions to separate and measure the clopidogrel intermediates and 5 related impurities thereof, and can effectively realize separation and quantitative measurement of the clopidogrel intermediates and 5 related substances thereof so as to reduce the influence of the impurities on the quality of a final clopidogrel product.
The method for detecting the clopidogrel intermediate and impurities adopts a high performance liquid chromatography to detect and analyze the clopidogrel intermediate and impurities, wherein a chromatographic column used in the high performance liquid chromatography is a chromatographic column with octadecylsilane chemically bonded silica gel as a filler;
the structural formula of the clopidogrel intermediate is as follows:
the impurities comprise first impurities, second impurities, third impurities, fourth impurities and fifth impurities, and the specific structural formula is as follows:
according to the high performance liquid chromatography, A, B mobile phases are used, the mobile phase A is methanol-phosphate buffer solution-acetonitrile with the volume ratio of 20:50:30-30:65:5, and the mobile phase B is methanol-phosphate buffer solution-acetonitrile with the volume ratio of 10:10:80-20:30:50, and a linear gradient elution mode is adopted.
The method according to the present invention, wherein the column used for high performance liquid chromatography is a column packed with octadecylsilane chemically bonded silica.
The method according to the invention, wherein the high performance liquid chromatography uses a column with a packing size of 4 to 10 μm, preferably a packing size of 5 μm.
The method according to the present invention, wherein the high performance liquid chromatography uses a column having an inner diameter of 3 to 10mm, preferably 4.6mm.
According to the method of the present invention, the column length of the chromatographic column used in the high performance liquid chromatography is 150 to 300mm, preferably 250mm.
According to the method of the present invention, wherein the high performance liquid chromatography uses a column packing size of 5 μm, an inner diameter of 4.6mm and a column length of 250mm. The above model parameters may be abbreviated as 5 μm by 4.6mm by 250mm, or other similar abbreviations.
The method according to the present invention, wherein the chromatographic column used for high performance liquid chromatography is a C18 chromatographic column.
The method according to the present invention, wherein the chromatographic column used for high performance liquid chromatography is a ZORBAX SB-C18 chromatographic column.
The method according to the invention, wherein the chromatographic column used for high performance liquid chromatography is a ZORBAX SB-C18 chromatographic column under the brand name Agilent.
The method according to the invention, wherein the column box temperature of the chromatographic column at the time of separation analysis by high performance liquid chromatography is 25 to 45 ℃, such as 25 to 30 ℃, such as about 30 ℃. The invention finds that the separation effect is quite good within the range of 25-30 ℃ of the column temperature box.
The method according to the invention, wherein the high performance liquid chromatography is using A, B two mobile phases. The mobile phase A is a mixed solution of methanol, acetonitrile and phosphate buffer solution, and the mobile phase B is a mixed solution of methanol, acetonitrile and phosphate buffer solution. The invention finds that mobile phase B has quite good separation effect in the range of methanol-phosphate buffer-acetonitrile (10:10:80) to methanol-phosphate buffer-acetonitrile (20:30:50) in the range of methanol-phosphate buffer-acetonitrile (20:50:30) to methanol-phosphate buffer-acetonitrile (30:65:5).
According to the method of the invention, wherein the high performance liquid chromatography is performed using A, B two mobile phases. Mobile phases A, B are all mixed solutions of methanol-phosphate buffer solution and acetonitrile. The elution mode is gradient elution. The specific linear elution procedure is as follows:
| time (minutes) | Mobile phase a (%) | Mobile phase B (%) |
| 0 | 30 | 70 |
| 10 | 30 | 70 |
| 25 | 0 | 100 |
| 65 | 0 | 100 |
| 66 | 30 | 70 |
| 80 | 30 | 70 |
The invention discovers that the linear elution is carried out according to the specific elution mode, and all related substances have quite good separation effect. In various embodiments of the present invention, all mobile phase elution is performed according to the linear elution procedure described above, unless otherwise specified.
In one embodiment, the mobile phase phosphate buffer has a pH of 2.0 to 8.0, such as a pH of 6.0 to 7.0, such as a pH of 6.0.+ -. 0.05. The invention has found that the separation effect is quite good in the pH value range of 6.0-7.0. The acid or base for adjusting the pH value includes acetic acid, formic acid, phosphoric acid, hydrochloric acid, ammonia water, etc., preferably phosphoric acid. In the experiments carried out in the following of the present invention, as not specifically described, mobile phases A, B were each methanol-phosphate buffer solution-acetonitrile mixed solution, and the pH values of mobile phases A, B were each 6.0.+ -. 0.05.
In one embodiment, the phosphate buffer is obtained by: about 3.48g to 1000ml of purified water of anhydrous dipotassium hydrogen phosphate is weighed, dissolved and mixed uniformly, and the pH value is regulated to 6.0+/-0.05 by phosphoric acid.
According to the method of the present invention, the flow rate of the mobile phase in the high performance liquid chromatography is 0.8ml/min to 1.2ml/min, and the flow rate of the mobile phase is preferably 1.0ml/min.
The method according to the invention, wherein the detector in high performance liquid chromatography is an ultraviolet detector. In one embodiment, the detection wavelength used is 215 to 225nm, with a preferred detection wavelength of 220nm.
According to the method of the invention, the measured concentration of the clopidogrel intermediate is 1-3 mg/ml, preferably 1.5-2.5 mg/ml, and preferably 2.0mg/ml.
The method according to the invention comprises the following steps:
(1) Preparing a test solution: taking a clopidogrel intermediate sample, adding a mixed solvent of methanol, acetonitrile and water to dissolve the clopidogrel intermediate sample, adding the mixed solvent of methanol, acetonitrile and water to fix the volume and preparing a solution of 1-3 mg/ml of the clopidogrel intermediate in each 1ml, particularly preparing a sample solution of 1.5-2.5 mg/ml, and preferentially preparing a sample concentration of 2.0 mg/ml;
(2) Preparation of control solution: precisely measuring the solution in the step (1), placing the solution in a 500ml volumetric flask, adding a mixed solvent of methanol, acetonitrile and water, diluting to a scale, shaking uniformly, and taking the mixed solvent as a control solution, wherein the concentration of the control solution is equal to 0.2% of that of a sample solution;
(3) Preparing a system applicability solution: dissolving a clopidogrel intermediate, an impurity I, an impurity II, an impurity III, an impurity IV and an impurity V by using a mixed solvent of methanol, acetonitrile and water, diluting and preparing about 2mg of the clopidogrel intermediate in each 1ml, and respectively 0.004mg of the impurity I, the impurity II, the impurity III, the impurity IV and the impurity V as a system applicability solution;
(4) Taking 5-25 mu l, preferably 15 mu l, of the solution in the step (1), the step (2) and the step (3), injecting the solution into a high performance liquid chromatograph, and reading at least one of the following information of impurities: the number of impurities, the types of impurities, the relative amounts of the impurities, the degree of separation between the respective chromatographic peaks, the peak areas of the respective chromatographic peaks;
(5) Reading impurity information according to the step (4), and calculating the contents of the first impurity, the second impurity, the third impurity, the fourth impurity and the fifth impurity according to a main component self-comparison method added with correction factors, wherein the calculation formulas of the contents of the first impurity, the second impurity, the third impurity, the fourth impurity and the fifth impurity are as follows: the peak area of impurity in the sample solution of step (1) is multiplied by the correction factor of impurity/the peak area of the main component of the control solution of step (2) is multiplied by 0.2, wherein the correction factor of impurity one is 0.67, the correction factor of impurity two is 1.0, the correction factor of impurity three is 0.92, the correction factor of impurity four is 0.68, and the correction factor of impurity five is 0.97. It should be noted that when the correction factor is between 0.9 and 1.1, it is considered that there is no significant difference in response, and calculation or determination may be performed without adding the correction factor; when the correction factor is between 0.2 and 5, the correction factor is substituted to calculate the test result or be used as the standard judgment basis; when the correction factor is less than 0.2 or more than 5, the self-control method should not be used for quantification or result judgment.
In the invention, the separation degree of clopidogrel intermediate and 5 impurities thereof is more than 2.
The beneficial effects of the invention are as follows:
according to the method for detecting clopidogrel intermediates and impurities, provided by the invention, the clopidogrel intermediates and 5 related impurities thereof are separated and measured by adopting specific reversed-phase high performance liquid chromatography analysis conditions, so that the separation and quantitative measurement of the clopidogrel intermediates and 5 related substances thereof can be effectively realized, and the influence of the impurities on the quality of the final clopidogrel product is reduced.
Drawings
FIG. 1 is a chromatogram of the applicability solution of example 1;
FIG. 2 is a chromatogram of the sample solution in example 1;
FIG. 3 is a chromatogram of the applicability solution in example 2;
FIG. 4 is a chromatogram of the sample solution in example 2;
FIG. 5 is a chromatogram of the applicability solution in example 3;
FIG. 6 is a chromatogram of the sample solution in example 3;
FIG. 7 is a chromatogram of the applicability solution in example 4;
FIG. 8 is a chromatogram of the sample solution in example 4;
FIG. 9 is a chromatogram of the applicability solution in example 5;
FIG. 10 is a chromatogram of the sample solution in example 5;
FIG. 11 is a chromatogram of the applicability solution in example 6;
FIG. 12 is a chromatogram of the sample solution in example 6.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (27:63:10) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (12:28:60) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature is 30 ℃; the flow rate of the mobile phase is 0.9ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: the clopidogrel intermediate (shown as LBGL003 in the diagram, the same applies hereinafter), the impurity one (shown as LBGL100 in the diagram, the same applies hereinafter), the impurity two (shown as LBGL200 in the diagram, the same applies hereinafter), the impurity three (shown as LBGL400 in the diagram, the same applies hereinafter), the impurity four (shown as LBGL500 in the diagram, the same applies hereinafter) and the impurity five (shown as LBGL600 in the diagram) are taken in appropriate amounts, and a mixed solvent of methanol, acetonitrile and water is added in appropriate amounts to dissolve, dilute and prepare a solution of about 2mg of the clopidogrel intermediate, 2mg of each 1ml of LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 as a system applicability solution.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
And precisely measuring 15 mu l of each of the system applicability solution and the sample solution, performing chromatographic analysis according to the chromatographic conditions, and recording chromatograms, wherein the results are respectively shown in fig. 1 and fig. 2.
As can be seen from fig. 1, the degree of separation between the known impurities, the unknown impurities and the main component in the system applicability solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system applicability solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are represented in fig. 1, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 1, RT12.622min is known LBGL100, RT3.596min is known LBGL200, RT13.622min is known LBGL400, RT8.698min is known LBGL500, RT46.753min is known LBGL600, and RT14.470min is clopidogrel intermediates LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 2, 1 impurity was detected in the sample solution, wherein RT3.644min is the known LBGL200, and the separation degree between each impurity and the main component in the sample solution is greater than 2.
Example 2:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (25:65:10) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (15:30:55) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature is 30 ℃; the flow rate of the mobile phase is 1.0ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: a solution of about 2mg of each of the clopidogrel intermediates, LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 per 1ml was prepared as a system applicability solution by dissolving a proper amount of each of the clopidogrel intermediates, LBGL100, LBGL400, LBGL500 and LBGL600 in a proper amount of a mixed solvent of methanol, acetonitrile and water, and diluting.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
And precisely measuring 15 mu l of each of the system applicability solution and the sample solution, performing chromatographic analysis according to the chromatographic conditions, and recording chromatograms, wherein the results are shown in fig. 3 and 4 respectively.
As can be seen from fig. 3, the degree of separation between the known impurities, the unknown impurities and the main component in the system applicability solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system-applicable solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are represented in fig. 3, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 3, RT12.630min is known as LBGL100, RT3.594min is known as LBGL200, RT13.630 min is known as LBGL400, RT8.701min is known as LBGL500, RT46.760min is known as LBGL600, and RT14.480min is known as clopidogrel intermediate LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 4, 1 impurity was detected in the sample solution, wherein RT3.973min is the known LBGL200, and the separation degree between each impurity and the main component in the sample solution is greater than 2.
Example 3:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (22:60:18) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (16:25:59) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature is 30 ℃; the flow rate of the mobile phase is 1.1ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: a solution of about 2mg of each of the clopidogrel intermediates, LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 per 1ml was prepared as a system applicability solution by dissolving a proper amount of each of the clopidogrel intermediates, LBGL100, LBGL400, LBGL500 and LBGL600 in a proper amount of a mixed solvent of methanol, acetonitrile and water, and diluting.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
The system applicability solution and the sample solution were measured precisely and 15. Mu.l each, the chromatographic analysis was performed according to the above chromatographic conditions, and the chromatograms were recorded, and the results were shown in FIG. 5 and FIG. 6, respectively.
As can be seen from fig. 5, the degree of separation between the known impurities, the unknown impurities and the main component in the system applicability solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system-applicable solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are represented in fig. 5, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 5, RT12.623min is known LBGL100, RT3.594min is known LBGL200, RT13.719 min is known LBGL400, RT8.695min is known LBGL500, RT46.771min is known LBGL600, and RT14.467min is clopidogrel intermediate LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 6, 1 impurity was detected in the sample solution, wherein RT3.560 min is the known LBGL200, and the degree of separation between each impurity and the main component in the sample solution is greater than 2.
Example 4:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (20:50:30) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (18:30:52) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature 25 ℃; the flow rate of the mobile phase is 1.0ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: a solution of about 2mg of each of the clopidogrel intermediates, LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 per 1ml was prepared as a system applicability solution by dissolving a proper amount of each of the clopidogrel intermediates, LBGL100, LBGL400, LBGL500 and LBGL600 in a proper amount of a mixed solvent of methanol, acetonitrile and water, and diluting.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
The system applicability solution and the sample solution were measured precisely and 15. Mu.l each, and were subjected to chromatographic analysis under the above-mentioned chromatographic conditions, and the chromatograms were recorded, with the results shown in FIG. 7 and FIG. 8, respectively.
As can be seen from fig. 7, the degree of separation between the known impurities, the unknown impurities and the main component in the system applicability solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system-applicable solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are represented in fig. 7, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 7, RT12.625min is known as LBGL100, RT3.292 min is known as LBGL200, RT13.6271 min is known as LBGL400, RT8.691min is known as LBGL500, RT46.781min is known as LBGL600, and RT14.469min is known as clopidogrel intermediates LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 8, 1 impurity was detected in the sample solution, wherein RT3.260min is the known LBGL200, and the separation degree between each impurity and the main component in the sample solution is greater than 2.
Example 5:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (30:65:5) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (20:20:60) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature is 30 ℃; the flow rate of the mobile phase is 1.0ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: a solution of about 2mg of each of the clopidogrel intermediates, LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 per 1ml was prepared as a system applicability solution by dissolving a proper amount of each of the clopidogrel intermediates, LBGL100, LBGL400, LBGL500 and LBGL600 in a proper amount of a mixed solvent of methanol, acetonitrile and water, and diluting.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
The system applicability solution and the sample solution were measured precisely and 15. Mu.l each, and were subjected to chromatographic analysis under the above-mentioned chromatographic conditions, and the chromatograms were recorded, with the results shown in FIG. 9 and FIG. 10, respectively.
As can be seen from fig. 9, the degree of separation between the known impurities, the unknown impurities and the main component in the system-applicable solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system-applicable solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are shown in fig. 9, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 9, RT12.629min is known as LBGL100, RT3.292 min is known as LBGL200, RT13.6271 min is known as LBGL400, RT8.697min is known as LBGL500, RT46.781min is known as LBGL600, and RT14.4638 min is known as clopidogrel intermediates LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 10, 1 impurity was detected in the sample solution, wherein RT3.553min is the known LBGL200, and the separation degree between each impurity and the main component in the sample solution is greater than 2.
Example 6:
instrument and conditions:
agilent 1260Infinity II high performance liquid chromatograph; a column (Agilent ZORBAX SB-C18,5 μm. Times.4.6 mm. Times.250 mm) packed with octadecylsilane chemically bonded silica, methanol-pH 6.0 phosphate buffer-acetonitrile (28:65:7) as mobile phase A, methanol-pH 6.0 phosphate buffer-acetonitrile (15:22:63) as mobile phase B, and linear gradient elution according to the elution gradient table above; the detection wavelength is 235nm; column Wen Xiangzhu temperature is 35 ℃; the flow rate of the mobile phase is 1.0ml/min; the liquid phase analysis sample volume was 15. Mu.l.
The test steps are as follows:
preparing a system applicability solution: a solution of about 2mg of each of the clopidogrel intermediates, LBGL100, LBGL200, LBGL400, LBGL500 and LBGL600 per 1ml was prepared as a system applicability solution by dissolving a proper amount of each of the clopidogrel intermediates, LBGL100, LBGL400, LBGL500 and LBGL600 in a proper amount of a mixed solvent of methanol, acetonitrile and water, and diluting.
Preparing a test solution: taking about 40mg of the clopidogrel intermediate, precisely weighing, placing into a 20ml measuring flask, adding a mixed solvent of methanol, acetonitrile and water, dissolving, diluting to a scale, and shaking uniformly to obtain the clopidogrel intermediate.
The system applicability solution and the sample solution were measured precisely and 15. Mu.l each, and were subjected to chromatographic analysis under the above-mentioned chromatographic conditions, and the chromatograms were recorded, with the results shown in FIG. 11 and FIG. 12, respectively.
As can be seen from fig. 11, the degree of separation between the known impurities, the unknown impurities and the main component in the system-applicable solution is greater than 2.0, so as to achieve effective separation, and the system applicability is good; in addition, the system applicability solution contains 6 specific added substances of clopidogrel intermediates and other 5 impurities, wherein the 6 substances are represented in fig. 1, and 5 impurities can be attributed by preparing a single impurity solution, for example, in fig. 1, RT12.623min is known LBGL100, RT3.292 min is known LBGL200, RT13.616min is known LBGL400, RT8.697min is known LBGL500, RT46.7825in is known LBGL600, and RT14.463min is known clopidogrel intermediates LBGL003. Other examples below may also readily attribute each substance.
As can be seen from FIG. 12, 1 impurity was detected in the sample solution, wherein RT3.616min is the known LBGL200, and the separation degree between each impurity and the main component in the sample solution is greater than 2.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiments or examples. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
While embodiments of the present invention have been shown and described, it will be understood by those of ordinary skill in the art that: many changes, modifications, substitutions and variations may be made to the embodiments without departing from the spirit and principles of the invention, the scope of which is defined by the claims and their equivalents.
Claims (8)
1. A method for detecting clopidogrel intermediates and impurities is characterized in that the clopidogrel intermediates and the impurities are detected and analyzed by adopting a high performance liquid chromatography, and a chromatographic column used by the high performance liquid chromatography is a chromatographic column with octadecylsilane chemically bonded silica gel as a filler;
the structural formula of the clopidogrel intermediate is as follows:
the impurities comprise first impurities, second impurities, third impurities, fourth impurities and fifth impurities, and the specific structural formula is as follows:
the high performance liquid chromatography uses A, B two mobile phases, wherein the mobile phase A is methanol-phosphate buffer solution-acetonitrile with the volume ratio of 20:50:30-30:65:5, and the mobile phase B is methanol-phosphate buffer solution-acetonitrile with the volume ratio of 10:10:80-20:30:50, and a linear gradient elution mode is adopted;
the high performance liquid chromatography separation analysis uses an ultraviolet detector or a diode array detector, and the detection wavelength is 215-225 nm;
the linear gradient elution was set as follows:
Wherein the flow rate of the mobile phase is 0.8 ml/min-1.2 ml/min.
2. The method for detecting clopidogrel intermediate and impurities according to claim 1, wherein the packing particle size of a chromatographic column used for the high performance liquid chromatography is 4-10 μm.
3. The method for detecting clopidogrel intermediate and impurities as set forth in claim 1, wherein the inner diameter of a column used for the high performance liquid chromatography is 3 to 10mm.
4. The method for detecting clopidogrel intermediate and impurities as set forth in claim 1, wherein the column length of the chromatographic column used for the high performance liquid chromatography is 150 to 300mm.
5. The method for detecting clopidogrel intermediate and impurities as set forth in claim 1, wherein the column temperature of the chromatographic column is 25 to 45 ℃ during the separation analysis by the high performance liquid chromatography.
6. The method for detecting clopidogrel intermediates and impurities according to claim 1, wherein the method specifically comprises:
(1) Preparing a test solution: taking a clopidogrel intermediate sample, adding a mixed solvent of methanol, acetonitrile and water to dissolve the clopidogrel intermediate sample, adding a mixed solvent of methanol, acetonitrile and water to fix the volume, and preparing a solution of 1-3 mg/ml of the clopidogrel intermediate in each 1 ml;
(2) Preparation of control solution: precisely measuring the solution in the step (1), placing the solution in a 500ml volumetric flask, adding a mixed solvent of methanol, acetonitrile and water, diluting to a scale, shaking uniformly, and taking the mixed solvent as a control solution, wherein the concentration of the control solution is equal to 0.2% of that of a sample solution;
(3) Preparing a system applicability solution: dissolving a clopidogrel intermediate, an impurity I, an impurity II, an impurity III, an impurity IV and an impurity V by using a mixed solvent of methanol, acetonitrile and water, diluting and preparing about 2mg of the clopidogrel intermediate in each 1ml, and respectively 0.004mg of the impurity I, the impurity II, the impurity III, the impurity IV and the impurity V as a system applicability solution;
(4) Taking 5-25 mu l of the solution in the step (1), the step (2) and the step (3), injecting the solution into a high performance liquid chromatograph, and reading at least one of the following information of impurities: the number of impurities, the types of impurities, the relative amounts of the impurities, the degree of separation between the respective chromatographic peaks, the peak areas of the respective chromatographic peaks;
(5) Reading impurity information according to the step (4), and calculating the contents of the first impurity, the second impurity, the third impurity, the fourth impurity and the fifth impurity according to a main component self-comparison method added with correction factors, wherein the calculation formulas of the contents of the first impurity, the second impurity, the third impurity, the fourth impurity and the fifth impurity are as follows: the peak area of impurity in the sample solution of step (1) is multiplied by the correction factor of impurity/the peak area of the main component of the control solution of step (2) is multiplied by 0.2, wherein the correction factor of impurity one is 0.67, the correction factor of impurity two is 1.0, the correction factor of impurity three is 0.92, the correction factor of impurity four is 0.68, and the correction factor of impurity five is 0.97.
7. The method for detecting clopidogrel intermediates and impurities according to claim 1, wherein the phosphate buffer solution adopts at least one of acetic acid, formic acid, phosphoric acid, hydrochloric acid, tartaric acid, oxalic acid and ammonia water to adjust the pH value.
8. The method for detecting clopidogrel intermediate and impurities as set forth in claim 7, wherein the pH of the phosphate buffer is 5.0 to 7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210659088.2A CN115060835B (en) | 2022-06-10 | 2022-06-10 | Clopidogrel intermediate and impurity detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210659088.2A CN115060835B (en) | 2022-06-10 | 2022-06-10 | Clopidogrel intermediate and impurity detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115060835A CN115060835A (en) | 2022-09-16 |
| CN115060835B true CN115060835B (en) | 2023-07-14 |
Family
ID=83200944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210659088.2A Active CN115060835B (en) | 2022-06-10 | 2022-06-10 | Clopidogrel intermediate and impurity detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115060835B (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008013500A1 (en) * | 2008-03-10 | 2009-09-17 | Evonik Degussa Gmbh | New chiral selectors and stationary phases for the separation of enantiomeric mixtures |
| CN101585842B (en) * | 2009-07-13 | 2011-07-20 | 北京赛科药业有限责任公司 | Research and control method of impurity B control method in clopidogrel |
| CN103387497A (en) * | 2012-05-10 | 2013-11-13 | 深圳信立泰药业股份有限公司 | Preparation methods for clopidogrel and its intermediates--methyl alpha-bromo-2-chloro-phenylacetate and thiophene ethylamino-substituted methyl acetate |
| CN103450005B (en) * | 2012-06-01 | 2016-07-06 | 深圳信立泰药业股份有限公司 | A kind of preparation method of clopidogrel and the alpha-brominated (2-Chlorophenyl)acetic acid of intermediate and α-thiophene ethamine base substituted acetic acid hydrochlorate |
| CN110862372B (en) * | 2019-12-03 | 2024-01-12 | 江西川奇药业有限公司 | Synthesis of clopidogrel intermediate (S) -2- (2-thiophenoethylamine) - (2-chlorophenyl) -methyl acetate |
| KR20220123058A (en) * | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition |
| CN112851631A (en) * | 2020-12-31 | 2021-05-28 | 宣城美诺华药业有限公司 | Impurity of clopidogrel hydrogen sulfate intermediate, preparation method and content control method thereof |
-
2022
- 2022-06-10 CN CN202210659088.2A patent/CN115060835B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115060835A (en) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114062554B (en) | Analysis method for simultaneously measuring related substances of acetaminophen ibuprofen | |
| CN104965041A (en) | High performance liquid chromatography detection method for parecoxib sodium isomer | |
| CN105510482B (en) | The detection method of isomer impurities content in a kind of ticagrelor raw material | |
| CN111983074A (en) | Method for determining peramivir intermediate isomer by using high performance liquid chromatography | |
| CN115060835B (en) | Clopidogrel intermediate and impurity detection method | |
| Rambla-Alegre et al. | Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases | |
| Pingale et al. | Development and validation of HPLC method for the determination of pregabalin in bulk and in pharmaceutical formulations | |
| CN106706769B (en) | Separation and determination method of empagliflozin and optical isomer thereof | |
| CN114965754B (en) | Method for detecting related substances and bacteriostat in acetaminophen tablet | |
| CN113702514A (en) | Method for determining atorvastatin calcium related impurity I | |
| CN110988158A (en) | Method for detecting related substances of tirofiban hydrochloride injection | |
| CN115586272A (en) | Detection method and application of brexpiprazole preparation dissolution | |
| CN113504317A (en) | Detection method and application of genotoxic impurities in apixaban | |
| CN116183753A (en) | Method for measuring content of pharmaceutical preparation containing acetaminophen, dextromethorphan hydrobromide and phenylephrine hydrochloride | |
| CN114414680B (en) | Method for measuring related substances in various small molecule anhydrides | |
| CN105125520A (en) | Celecoxib preparation and preparing method and control method of celecoxib preparation | |
| Hassouna et al. | Novel RP-HPLC-DAD and RP-UPLC Methods for Simultaneous Determination of Cefaclor and Methylparaben in their Dosage form and in its Impurity Cefaclor-Delta-3-Isomer | |
| CN110824074A (en) | Method for detecting related substances of ticagrelor by using high performance liquid chromatography | |
| CN109765316B (en) | Method for detecting levetiracetam from medicine | |
| CN113933400B (en) | Detection method of genotoxic impurities in dabigatran etexilate bulk drug or preparation | |
| Krzek et al. | Validation of a method for simultaneous determination of menthol and methyl salicylate in pharmaceuticals by capillary gas chromatography with cool on-column injection | |
| CN111679004A (en) | Quality control method of probucol | |
| CN112964794B (en) | Method for separating and detecting 4,5,6,7-tetrahydrothiophene [3,2-c ] pyridine hydrochloride and related substances thereof | |
| CN106855542A (en) | Method of the high performance liquid chromatography detection metadoxine about material | |
| CN116297908B (en) | Analysis method of indobufen isomer impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221024 Address after: No. 855, Tianxiang North Avenue, High tech Zone, Nanchang City, Jiangxi Province 330000 Applicant after: JIANGXI CHUANQI PHARMACEUTICAL Co.,Ltd. Applicant after: Nanchang University Address before: Room 66A #, 66B #, 67 #, 68 #, 69A #, 69B #, 187-1 # to Room 66A # 101, Building 6 #, Nanchang Jiahai Industrial Park, No. 2799, Tianxiang Avenue, Nanchang Hi tech Industrial Development Zone, Nanchang City, Jiangxi Province, 330000 Applicant before: NANCHANG CITY BOZEKANG PHARMACEUTICAL Co.,Ltd. Applicant before: Nanchang University |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |